| Literature DB >> 27163423 |
Nelson Américo Hossne Junior1, Matheus Miranda1, Marcus Rodrigo Monteiro1, João Nelson Rodrigues Branco1, Guilherme Flora Vargas1, José Osmar Medina de Abreu Pestana1, Walter José Gomes1.
Abstract
OBJECTIVE: Coronary artery bypass grafting is currently the best treatment for dialysis patients with multivessel coronary artery involvement. Vasoplegic syndrome of inflammatory etiology constitutes an important postoperative complication, with highly negative impact on prognosis. Considering that these patients have an intrinsic inflammatory response exacerbation, our goal was to evaluate the incidence and mortality of vasoplegic syndrome after myocardial revascularization in this group.Entities:
Mesh:
Year: 2015 PMID: 27163423 PMCID: PMC4614932 DOI: 10.5935/1678-9741.20140092
Source DB: PubMed Journal: Rev Bras Cir Cardiovasc
Demographic characteristics, according to the use of cardiopulmonary bypass.
| Demographic Characteristics | CPB | Off-pump | |
|---|---|---|---|
| n | 20 | 30 | 0.68 |
| Age (years) | 57.1 | 56.1 | 0.96 |
| Female gender (%) | 20 | 37 | 0.34 |
| Dialysis time (months) | 3.5 | 5.0 | 0.68 |
| Hypertension (%) | 100 | 100 | 1.00 |
| Diabetes (%) | 70 | 72.6 | 0.95 |
| Dyslipidemia (%) | 50 | 37 | 0.52 |
| Obesity (%) | 5 | 20 | 0.22 |
| Smoking (%) | 15 | 7 | 0.38 |
| COPD(%) | 0 | 0 | 1.00 |
| Previous stroke (%) | 15 | 17 | 1.00 |
| Previous coronary stenting (%) | 25 | 27 | 0.84 |
| Previous cardiac surgery (%) | 0 | 0 | 1.00 |
| Congestive heart failure (%) | 25 | 23 | 0.81 |
| Previous myocardial infarction (%) | 15 | 20 | 0.72 |
| Peripheral artery disease (%) | 15 | 20 | 0.72 |
| Stable angina (%) | 10 | 17 | 0.69 |
| Unstable angina (%) | 15 | 13 | 0.99 |
| Left main disease (%) | 15 | 17 | 1.00 |
| LV ejection fraction > 50% | 80 | 77 | 1.00 |
| EuroSCORE II | 2.5 | 2.8 | 0.83 |
COPD=chronic obstructive pulmonary disease; CPB=cardiopulmonary bypass; LV=left ventricle; Left main disease=obstructive lesion greater than 50%
Intraoperative variables, according to the use ofcardiopulmonary bypass.
| Intraoperative variable | CPB | Off-pump | |
|---|---|---|---|
| Number of coronary anastomosis | 2.8 | 1.8 | <0.0001 |
| Inotropic support (%) | 85 | 40 | 1.00 |
| Blood transfusion (%) | 65 | 23 | 0.008 |
Incidence of postoperative vasoplegia, according to the use cardiopulmonary bypass.
| Vasoplegia | CPB | Off-pump |
|
|---|---|---|---|
| Incidence (%) | 30 | 3 | 0.01 |
Vasoplegic subgroup characteristics, according to the use of cardiopulmonary bypass.
| Vasoplegic subgroup | CPB | Off-pump | ||
|---|---|---|---|---|
| n | 6 | 1 | 0.01 | |
| AAS | 100% | 100% | 1.00 | |
| Preoperative | Beta-blocker | 83.3% | 100% | 1.00 |
| medication | ACE inhibitor | 16.7% | 0% | 1.00 |
| Statin | 100% | 100% | 1.00 | |
| LV ejection fraction > 50% | 100% | 100% | 1.00 | |
| Diabetes (%) | 66.7% | 100% | 1.00 | |
Average ± standard deviation (in minutes) of bypass and aortic cross clamp times, according to the development of postoperative vasoplegia.
| Mean time ± standard deviation | Vasoplegia | No vasoplegia | |
|---|---|---|---|
| Bypass | 102.7±20.5 | 81.3±29.3 | 0.08 |
| Aortic cross clamp | 58.5±16.6 | 56.3±21.0 | 0.90 |
| ACE | Angiotensin-converting enzyme |
| ACT | Activated clotting time |
| CABG | Coronary artery bypass grafting |
| CI | Cardiac index |
| COPD | Chronic obstructive pulmonary disease |
| CPB | Cardiopulmonary bypass |
| CRF | Chronic renal failure |
| LV | Left ventricle |
| MAP | Mean arterial pressure |
| OPCAB | Off-pump coronary artery bypass. |
| SVRI | Systemic vascular resistance index |
| NAHJ | Analysis and/or data interpretation; conception and design study; final manuscript approval; manuscript writing or critical review of its content; conduct of operations and/or trials; statistical analysis |
| MM | Analysis and/or data interpretation; conception and design study; final manuscript approval; manuscript writing or critical review of its content; statistical analysis |
| MRM | Analysis and/or data interpretation, conception and design study; final manuscript approval; manuscript writing or critical review of its content |
| JNRB | Analysis and/or data interpretation; conception and design study; final manuscript approval; manuscript writing or critical review of its content; conduct of operations and/or trials; statistical analysis |
| GFV | Final manuscript approval; manuscript writing or critical review of its content; conduct of operations and/or trials |
| JOMAP | Analysis and/or data interpretation; conception and design study; final manuscript approval; manuscript writing or critical review of its content |
| WJG | Analysis and/or data interpretation; final manuscript approv-al; manuscript writing or critical review of its content |